drugset / Trial / NCT03187301

A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes

NCT03187301

Phase 2 Completed 48 enrolled Sumitomo Pharma America, Inc.
RandomizedCrossoverQuadruple-blindTreatment

Summary

A cardiac safety study of an investigational drug to see how it affects the heart in people with Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)

Timeline

Start
2017-08-03
Primary completion
2017-12-21
Completion
2017-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Apomorphine Unknown
Comparator Moxifloxacin Small molecule 400 mg

Indications